<DOC>
	<DOCNO>NCT00930020</DOCNO>
	<brief_summary>Background : Stroke lead cause death chronic serious disability worldwide . Minocycline , semisynthetic tetracycline , consistently show recent year neuroprotective animal model brain ischemia . Furthermore , small , open label study do human acute ischemic stroke publish late last year show minocycline , administer 5 day , within 6 24 hour stroke onset highly effective improve functional outcome even early 7 day stroke onset . However , well-conducted , randomize control translational study use minocycline currently lack . Objective : To determine minocycline , administer within 3 48 hour acute ischemic stroke onset superior placebo reduce neurological deficit improve functional outcome 90 day post stroke . Methods : The investigator plan multi-centre randomized , double-blind , placebo control trial ischemic stroke patient randomize treatment either oral minocycline placebo within 3 48 hour symptom onset . The primary efficacy endpoint modify Rankin scale ( mRS ) score randomized subject 90 day . Secondary endpoint include improvement NIH Stroke Scale ( NIHSS ) score baseline Barthel index 90 day . NeuMAST test follow hypothesis : Primary Hypothesis : Minocycline , compare placebo , administer 3 48 hour onset acute ischemic stroke improve recovery functional outcome assess mRS score day 90 post-stroke . Secondary Hypotheses : 1 . Minocycline compare placebo , administer 3 48 hour onset acute ischemic stroke improve recovery functional outcome assess improvement NIHSS score day 90 post-stroke . 2 . Minocycline compare placebo , administer 3 48 hour onset acute ischemic stroke improve functional outcome assess Barthel Index ( BI ) score day 90 post-stroke . 3 . Minocycline , compare placebo reduces 90 day risk recurrent stroke , MI death administer 3 48 hour acute ischemic stroke onset . A positive result significant impact management acute ischemic stroke pave way future study aim find optimal dose formulation minocycline treat acute ischemic stroke .</brief_summary>
	<brief_title>Neuroprotection With Minocycline Therapy Acute Stroke Recovery Trial</brief_title>
	<detailed_description>A ) Specific Primary Objective : 1 . To determine minocycline , administer within 3 48 hour acute ischemic stroke onset superior placebo reduce neurological deficit improve functional outcome day 90 post stroke . B ) Specific Secondary Objectives : 1 . To determine minocycline administer within 3 48 hour acute ischemic stroke onset superior placebo reduce 90 day risk recurrent ischemic stroke , myocardial infarction ( MI ) death . 2 . To study compare differential efficacy minocycline administer state , four stroke subtypes accord TOAST criterion , i.e . lacunar stroke , large vessel atherosclerosis , cardioembolic cryptogenic stroke C ) Primary Efficacy Endpoint : The primary efficacy endpoint modify Rankin scale score 90 day randomize patient . Favorable outcome day 90 define achieve mRS score 0 1 . Last observation carry forward ( LOCF ) use subject without assessment primary efficacy variable Day 90 . Deaths assign score 6 . D ) Secondary Endpoint measure : 1 . NIHSS score day 90 . 2 . Difference NIHSS score baseline day 7 ( plus minus 2 day ) 90 post stroke . ( Favorable outcome day 90 define achieve decrease &gt; 6 point NIHSS baseline NIHSS &lt; 1 day 90 . 3. mRS score day 7 ( plus minus 2 day ) 30 post stroke . 4 . Barthel index day 90 . ( A score &gt; 85 define good outcome ) 5 . First documentation follow-up ischemic stroke , myocardial infarction death cause . Recruitment study subject : Acute ischemic stroke patient admit NNI ( TTSH campus ) CGH ASU study period eligible participate study base criterion state invited participate study . Approximately 1300 800 patient acute ischemic stroke admit NNI ( TTSH campus ) CGH ASU respectively per year . The time window enrolment within 3 48 hour symptom onset . For patient find stroke awaken , assume stroke occur last time patient know normal . All eligible patient identify ward on-call Neurology/Medical team refer study research assistants investigator ; screen patient participation trial . STUDY INTERVENTION The assigned treatment , i.e. , Minocycline 200mg match placebo administer daily 5 consecutive day soon inform consent take patient enrol study . Follow-up Assessment : The neurologic deficit , global functional ability level handicap score use NIH Stroke Scale ( NIHSS ) modify Rankin scale ( mRS ) baseline day 7 ( plus minus 2 day ) . On day 30 post-stroke , telephone assessment additional question perform obtain mRS score , document recurrent stroke , MI death . On day 90 , addition neurological evaluation , mRS NIHSS scoring , Barthel Index ( BI ) score , measure independence activity daily live , obtained subject .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Singapore citizen permanent resident Age range 21 80 year NIHSS equal 5 less 22 time admission Clinical diagnosis acute ischemic stroke accord WHO criteria Onset stroke 3 48 hour prior start treatment Must work telephone line Long term resident Institutions Nursing home Patients significant baseline cognitive dysfunction Patients hemorrhagic stroke Prestroke MRS 1 Evidence disease CNS ( i.e. , brain tumor , CNS infection ) Known allergic response tetracycline Acute Chronic renal failure Hepatitis liver disease Preexisting infectious disease require antibiotic Receipts IV rTPA Participation another clinical trial precede 3 month Unable unwilling provide inform consent Unwilling return frequent clinic visit Geographic social factor make study participation impractical</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>ischemic stroke recovery</keyword>
	<keyword>minocycline</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>acute stroke</keyword>
</DOC>